Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of ...

Apellis Pharmaceuticals Inc. will escape an investor lawsuit alleging it concealed safety risks connected to its ...

In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other most oversold healthcare stocks to buy now. Healthcare costs and spending ...

Signaturefd LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 357.2% during the 4th ...

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

In a report released on March 21, Umer Raffat from Evercore ISI maintained a Buy rating on Apellis Pharmaceuticals (APLS – Research Report).

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few ...

Last week, Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a fourth-quarter earnings loss of 29 cents per share, beating the consensus loss of 37 cents. Sales increased 45.2% to $212.5 million ...